Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

7.04
+0.08001.15%
Volume:57.92K
Turnover:409.32K
Market Cap:43.56M
PE:-2.87
High:7.36
Open:7.06
Low:6.82
Close:6.96
52wk High:13.69
52wk Low:3.76
Shares:6.19M
Float Shares:3.00M
Volume Ratio:1.44
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4500
EPS(LYR):-2.4500
ROE:-196.92%
ROA:-69.33%
PB:0.81
PE(LYR):-2.87

Loading ...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 12, 2025

Aligos Therapeutics Reports Positive Phase 1 Results for Pevifoscorvir Sodium in Chronic Hepatitis B

Reuters
·
Dec 11, 2025

Aligos Therapeutics Showcases Positive Data at HEP-DART 2025 Meeting

Reuters
·
Dec 11, 2025

Piper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)

TIPRANKS
·
Nov 25, 2025

Aligos Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Nov 14, 2025

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Nov 14, 2025

Aligos Therapeutics Reports Positive 96-Week Data for Pevifoscorvir Sodium in Chronic Hepatitis B

Reuters
·
Nov 10, 2025

Aligos Therapeutics: Strategic Execution and Promising Pipeline Drive Buy Rating

TIPRANKS
·
Nov 10, 2025

Aligos Therapeutics Q3 EPS $(3.04) Misses $(2.27) Estimate, Sales $741.000K Beat $500.000K Estimate

Benzinga
·
Nov 06, 2025

Aligos Therapeutics Inc: Cash, Cash Equivalents and Investments Are Expected to Provide Sufficient Funding of Planned Operations Into Q3 of 2026

THOMSON REUTERS
·
Nov 06, 2025

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

GlobeNewswire
·
Nov 06, 2025

Aligos Therapeutics Inc expected to post a loss of $1.90 a share - Earnings Preview

Reuters
·
Nov 04, 2025

Aligos Therapeutics to Present at Jefferies London Healthcare Conference

Reuters
·
Nov 04, 2025

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire
·
Oct 30, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30, 2025

Aligos Therapeutics (ALGS) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Oct 28, 2025

Aligos Therapeutics’ Promising Hepatitis B Study: A Potential Game-Changer?

TIPRANKS
·
Oct 28, 2025

Aligos Therapeutics announces inducement grants under Nasdaq listing rule

TIPRANKS
·
Oct 17, 2025

Aligos Therapeutics Receives Usan Council Approval for Pevifoscorvir Sodium as Nonproprietary Name for Alg-000184

THOMSON REUTERS
·
Oct 16, 2025

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

GlobeNewswire
·
Oct 16, 2025